Defining Quality in HCT

Health care systems in the U.S. and worldwide face enormous pressure from rising costs, demand for care, quality improvement, and innovation in care delivery and payment models.

Learn about current quality measures in HCT and what industry stakeholders recommend for the future.

Measures of Today: Outcomes and Cost 

To date, the effectiveness of HCT has only been measured by patient 1-year outcomes. While this is an important measure, Medicare and other payers are moving towards expanded pay for value programs and reimbursement models which will require additional ways to quantify the quality and outcomes of HCT.

Learn more about value based purchasing goals of the future.

Defining Quality and Value in the Future

The NMDP/Be The Match is leading a broad base of individuals and health care organizations – including physicians, transplant recipients, HCT program administrators, national payers, reinsurers, and researchers to expand thinking around how to demonstrate that HCT is an appropriate, cost-effective, and high-quality treatment option for a wide range of diseases. 

These leaders believe that in addition to outcomes, quality and value in HCT will be best demonstrated by also measuring performance in the following areas: